4//SEC Filing
Holtzman Douglas 4
Accession 0001209191-23-023467
CIK 0001786255other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 7:12 PM ET
Size
11.8 KB
Accession
0001209191-23-023467
Insider Transaction Report
Form 4
Icosavax, Inc.ICVX
Holtzman Douglas
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-04-03$6.08/sh−20,143$122,439→ 290,354 total - Exercise/Conversion
Common Stock
2023-04-03$1.04/sh+20,443$21,261→ 310,497 total - Sale
Common Stock
2023-04-03$6.56/sh−300$1,968→ 290,054 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-03−20,443→ 44,977 totalExercise: $1.04Exp: 2031-01-28→ Common Stock (20,443 underlying)
Holdings
- 2,792(indirect: By Stanley Holtzman)
Common Stock
Footnotes (4)
- [F1]The sales reported herein were made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on December 2, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $6.52. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.
- [F4]25% of the shares subject to the option vested on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
Documents
Issuer
Icosavax, Inc.
CIK 0001786255
Entity typeother
Related Parties
1- filerCIK 0001874371
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 7:12 PM ET
- Size
- 11.8 KB